2020 Pediatric Rheumatology Symposium

April 29-May 2, 2020

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

View by Number View by Title View Sessions

View by Date

Saturday, May 2, 2020

4:15PM-5:15PM: Abstract Number: 148

Chronic Fatigue Symptoms in Children with Abrupt Early-onset OCD And/or PANS

Poster Session 3

4:15PM-5:15PM: Abstract Number: 132

Clinical Characteristics and Outcomes of Critically Ill Children Requiring Rheumatology Consultation in a Large Intensive Care Unit

Poster Session 3

4:15PM-5:15PM: Abstract Number: 183

Collaboration Between Rheumatology Clinic and Specialty Pharmacy to Positively Impact Patient Experience and Hospital Stewardship

Poster Session 3

4:15PM-5:15PM: Abstract Number: 126

Cyclophosphamide as Rescue Therapy for Kawasaki Disease with Peripheral Vascular Disease: A Single Center Experience

Poster Session 3

4:15PM-5:15PM: Abstract Number: 141

Cyclophosphamide Use in Treatment of Refractory Kawasaki Disease: A Single Center Case Series of 10 Patients and Literature Review

Poster Session 3

4:15PM-5:15PM: Abstract Number: 127

Disease Characteristics and Medication Utilization in Lupus Nephritis Associated with Childhood-Onset Systemic Lupus Erythematosus

Poster Session 3

4:15PM-5:15PM: Abstract Number: 121

Evaluating the Relationship Between Juvenile Idiopathic Arthritis Disease Activity and Uveitis Activity: A Retrospective Analysis

Poster Session 3

4:15PM-5:15PM: Abstract Number: 113

Evaluation of B-cell Depletion with Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease

Poster Session 3

4:15PM-5:15PM: Abstract Number: 134

Evaluation of Self-report Screening Measures in the Detection of Depressive and Anxiety Disorders Among Children and Adolescents with Systemic Lupus Erythematosus

Poster Session 3

4:15PM-5:15PM: Abstract Number: 193

Examining Social Loafing and the Free-Rider Effect in Transition Readiness Among Youth with jSLE

Poster Session 3

4:15PM-5:15PM: Abstract Number: 168

Examining the Role of IFN-I and Langerhans Cell ADAM17 in Lupus Photosensitivity

Poster Session 3

4:15PM-5:15PM: Abstract Number: 144

Failure of Methotrexate Monotherapy and Subsequent Response to Tumor Necrosis Factor Inhibitors in Pediatric Non-Infectious Uveitis

Poster Session 3

4:15PM-5:15PM: Abstract Number: 147

Familial Clustering of Immune-mediated Diseases in Children with Abrupt-onset OCD

Poster Session 3

4:15PM-5:15PM: Abstract Number: 117

Family Impact of Juvenile Localized Scleroderma

Poster Session 3

4:15PM-5:15PM: Abstract Number: 125

Feasibility and Pilot Study of Mental Health Screening in Juvenile Myositis

Poster Session 3

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].